Home › Funds › Spruce Street Capital LP › ELVN
Spruce Street Capital LP position in ELVN
ENLIVEN THERAPEUTICS INC · Health Care
Spruce Street Capital LP reported holding 329,006 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$15.1M, representing 2.40% of its reported portfolio and ranking #13 among its reported holdings. Spruce Street Capital LP has disclosed ELVN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Spruce Street Capital LP's ELVN position evolved
Spruce Street Capital LP first disclosed a stake in ELVN in Q4 2025 at 446,084 shares (US$6.9M). The position peaked in Q2 2026 at 329,006 shares, worth US$16.7M. Across 4 filings, Spruce Street Capital LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 329,006 shares valued at US$15.1M. Notable position changes include a 26% trim in Q1 2026 (shares rose 29% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 446.08K | $6.87M | New |
| Q1 2026 | 329.01K | $12.90M | Reduce |
| Q2 2026 | 329.01K | $16.70M | Hold |
| Q3 2026 | 329.01K | $15.08M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELVN and 13F data
ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 64 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$326.4M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELVN
- ORBIMED ADVISORS LLC 6.78M sh · $343.91M · Q2 2026
- Polar Capital Holdings Plc 6.43M sh · $326.35M · Q2 2026
- Vestal Point Capital, LP 4.00M sh · $203.00M · Q2 2026
- Commodore Capital LP 3.27M sh · $166.21M · Q2 2026
- Fairmount Funds Management LLC 1.86M sh · $94.17M · Q2 2026
- Bellevue Group AG 1.49M sh · $75.62M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $69.06M · Q2 2026
- Siren, L.L.C. 1.48M sh · $67.62M · Q3 2026
- Novo Holdings A/S 1.00M sh · $50.75M · Q2 2026
- First Turn Management, LLC 954.36K sh · $48.43M · Q2 2026
- SAMLYN CAPITAL, LLC 912.64K sh · $46.32M · Q2 2026
- BAKER BROS. ADVISORS LP 905.19K sh · $45.94M · Q2 2026
More on Spruce Street Capital LP
FAQ
How long has Spruce Street Capital LP held ELVN?
Spruce Street Capital LP has disclosed ELVN holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Spruce Street Capital LP's current position in ELVN?
As of Q3 2026, Spruce Street Capital LP holds 329.01K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $15.08M, representing 2.40% of its reported portfolio and ranking #13.
Has Spruce Street Capital LP been buying or selling ELVN?
In the latest 13F filing (Q3 2026), Spruce Street Capital LP held unchanged its position in ELVN. The position peaked in Q2 2026 at 329.01K shares.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.